In this specific case, CBM can be characterized as a spectral bipolar disease, and when a CD4+ Th1 immune response tends to develop, atrophic skin lesions can be observed in patients with CBM, but patients that mount a CD4+ Th2 immune response (Figure 5) show severe types of lesions, such as tumoral and verrucous types [136]. The gene discussed is CD4; the disease is glycogen storage disease VI.